Hoofddorp, the Netherlands, 6 May 2020. IGEA Pharma N.V. (SIX: IGPH) today announced that an evaluation by the Histocompatibility Laboratories, Department of Surgery, University of Miami – Miller School of Medicine suggests that the IGEA’s COVID-19 antibody rapid test appears to be superior to an established ELISA procedure in detecting IgM and IgG antibodies.Continue reading →
Hoofddorp, the Netherlands, 4 May 2020. IGEA Pharma N.V. (SIX: IGPH) today announced a further extension of the partnership with Acalis by signing an agreement for the wholesale distribution of the Alzheimer’s prevention kit ‘Alz1’ in the US.Continue reading →
Hoofddorp, the Netherlands, 30 April 2020. IGEA Pharma (SIX: IGPH) today announced the grant of a temporary exemption from its disclosure obligations with respect to the 2019 annual report.Continue reading →
Hoofddorp, the Netherlands, 6 April 2020. IGEA Pharma (SIX: IGPH) today announced to starting supply of a COVID-19 antibody test following an agreement signed with a PRC independent SARS-CoV-2 IgM/IgG test developer and manufacturer.Continue reading →
Hoofddorp, the Netherlands, 18 March 2020. IGEA Pharma (SIX: IGPH) today announced an explosion in the demand for dry aerosol devices in Italy as a result of the COVID-19 outbreak so severely affecting this country.Continue reading →
Hoofddorp, the Netherlands, 12 February 2020. IGEA Pharma N.V. (SIX: IGPH) today announced its intention to acquire a majority stake in Medical Jet Srl (“Medical Jet”), a privately held company operating in the pathogen’s decontamination of air and inanimate environmental surfaces and in air
sterilization and purification. A memorandum of understanding has been signed and subject to the satisfaction of certain customary conditions for a transaction of this type, IGEA expect to close the acquisition by June 2020. Further details of the transaction were not disclosed at this stage.
Hoofddorp, the Netherlands, 8 January 2020. IGEA Pharma N.V. (SIX: IGPH) today announced that the extraordinary general meeting followed all recommendations of the company. The minutes of the extraordinary general meeting is available at igeapharma.nl/category/information-for-shareholdersContinue reading →
This press release complements today’s announcement “IGEA calls extraordinary general meeting” to be viewed here.
Hoofddorp, the Netherlands, 3 December 2019. IGEA Pharma N.V. (SIX: IGPH) today announced changes in its supervisory board. As announced today by separate press release, IGEA proposes to its shareholders to amend the articles of association by introducing a one-tier board structure with executive and non-executive directors. The current supervisory board will be abolished as a corporate body in connection with this proposed amendment. Giovanni Ferrario and Mark de Simone, chairman and member, respectively, of the current supervisory board, will stand for election as non-executive directors. Federico Bazzoni and Flavio Peralda resigned and will no longer serve as directors.Continue reading →
FOR RELEASE IN SWITZERLAND – THIS IS A RESTRICTED COMMUNICATION AND YOU MUST NOT FORWARD IT OR ITS CONTENTS TO ANY PERSON TO WHOM FORWARDING THIS COMMUNICATION IS PROHIBITED. NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN THE UNITED STATES, AUSTRALIA, CANADA OR JAPAN.
Hoofddorp, the Netherlands, 3 December 2019. IGEA Pharma N.V. (SIX: IGPH) today announced the convening of an extraordinary general meeting (the “EGM”) for Wednesday, 8 January 2020. The EGM will resolve on the acquisition of the spin-off of Meditalia S.r.l. and on the proposal to authorize the management board to issue new shares (with respect to the acquisition of Meditalia, see also IGEA’s press release of 20 November 2019). IGEA plans to raise approximatively EUR 5 million gross proceeds through a capital increase in order to finance the further commercialization of its product portfolio which will include also the med-tech products of the planned spin-off of Meditalia S.r.l. IGEA expects to carry out its fundraising between March and April 2020. As previously announced, up to EUR 1 million new funds are committed by certain of the current shareholders of Meditalia S.r.l.Continue reading →